Next Article in Journal
Early Insights from Commercialization of Gene Therapies in Europe
Previous Article in Journal
The Intra-S Checkpoint Responses to DNA Damage
Review

Immune-Mediated Therapies for Liver Cancer

1
Department of Electrical and Computer Engineering, University of Minnesota, 200 Union Street S.E., Minneapolis, MN 55455, USA
2
Departments of Medicine and Genetics, Cell Biology and Development, University of Minnesota, 420 Delaware Street S.E., Minneapolis, MN 55455, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Selvarangan Ponnazhagan
Genes 2017, 8(2), 76; https://doi.org/10.3390/genes8020076
Received: 27 November 2016 / Revised: 6 February 2017 / Accepted: 13 February 2017 / Published: 17 February 2017
(This article belongs to the Section Human Genomics and Genetic Diseases)
In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologous immune cells, and stimulation of host immunity by targeting tumor-evasive mechanisms have advanced cancer immunotherapy. In addition, studies on innate immunity and mechanisms of immune evasion have enhanced our understanding on the immunology of liver cancer. Preclinical and clinical studies with immune-mediated therapies have shown potential benefits in patients with liver cancer. In this review, we summarize current knowledge and recent developments in tumor immunology by focusing on two main primary liver cancers: hepatocellular carcinoma and cholangiocarcinoma. View Full-Text
Keywords: adaptive immunity; adoptive cell transfer; cancer vaccines; cholangiocarcinoma; hepatocellular carcinoma; immune checkpoint blockade; immunotherapy; innate immunity; tumor immunology adaptive immunity; adoptive cell transfer; cancer vaccines; cholangiocarcinoma; hepatocellular carcinoma; immune checkpoint blockade; immunotherapy; innate immunity; tumor immunology
Show Figures

Figure 1

MDPI and ACS Style

Aravalli, R.N.; Steer, C.J. Immune-Mediated Therapies for Liver Cancer. Genes 2017, 8, 76. https://doi.org/10.3390/genes8020076

AMA Style

Aravalli RN, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes. 2017; 8(2):76. https://doi.org/10.3390/genes8020076

Chicago/Turabian Style

Aravalli, Rajagopal N., and Clifford J. Steer. 2017. "Immune-Mediated Therapies for Liver Cancer" Genes 8, no. 2: 76. https://doi.org/10.3390/genes8020076

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop